Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study-Reference-Cited by-同舟云学术

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Published:2013-05 Issue:6 Volume:14 Page:461-471
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Swain Sandra M,Kim Sung-Bae,Cortés Javier,Ro Jungsil,Semiglazov Vladimir,Campone Mario,Ciruelos Eva,Ferrero Jean-Marc,Schneeweiss Andreas,Knott Adam,Clark Emma,Ross Graham,Benyunes Mark C,Baselga José

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist,2009

2. Confirmation of a low HER2 positivity rate of breast carcinomas: limitations of immunohistochemistry and in situ hybridization;Vogel;Diagn Pathol,2010

3. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

4. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review;Dawood;J Clin Oncol,2010

5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

Cited by 835 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series;Frontiers in Oncology;2024-08-16

2. GluOC promotes proliferation and metastasis of TNBC through the ROCK1 signaling pathway;Cancer Cell International;2024-07-25

3. Dapagliflozin for the primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy: design of the multi-center phase II randomized PROTECT trial;2024-07-24

4. The Prognostic Impact of HER2-Low and Menopausal Status in Triple-Negative Breast Cancer;Cancers;2024-07-17

5. Cost Evaluation of Subcutaneous Trastuzumab Versus Intravenous Trastuzumab for the Treatment of HER2-Positive Breast Cancer: Insights From Oncology Hospitals in Morocco;European Journal of Oncology Pharmacy;2024-07